SCHEMBL30714743

SCHEMBL30714743

Cn1nccc1COc1ccc2nn(C)c(C(=O)NCCN3CCOC3=O)c2c1

nearest known ligand 0.42

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
SCN9A Q15858 2/20 0.42
HPGDS O60760 2/20 0.38
PLAT P00750 1/20 0.36
POLB P06746 4/20 0.35
MAPT P10636 3/20 0.35
ALDH1A1 P00352 2/20 0.35
LMNA P02545 1/20 0.35
TDP1 Q9NUW8 1/20 0.35
KMT2A Q03164 1/20 0.35
NQO2 P16083 1/20 0.35
CYP11B2 P19099 1/20 0.35
NTRK1 P04629 1/20 0.35
KDM4E B2RXH2 1/20 0.34
GLA P06280 1/20 0.34
THRB P10828 1/20 0.34
TAS1R3 Q7RTX0 1/20 0.33
TAS1R1 Q7RTX1 1/20 0.33
TAS1R2 Q8TE23 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30714710 0.87 NAAA (0.44) SCN9APOLBMAPTALDH1A1LMNA
SCHEMBL30714645 0.84 SCN9A (0.41) SCN9AHPGDSPLATPOLBMAPT
SCHEMBL30714746 0.83 SCN9A (0.45) SCN9AHPGDSPOLBMAPTALDH1A1
SCHEMBL30714587 0.78 ALDH1A1 (0.47) ALDH1A1KMT2AKDM4E
SCHEMBL30714704 0.77 HPGDS (0.38) HPGDSPOLBMAPTALDH1A1KMT2A
SCHEMBL26696010 0.77 HPGDS (0.41) HPGDSMAPTLMNAKMT2ACYP11B2
SCHEMBL30714742 0.77 SLC6A5 (0.40)
SCHEMBL26696001 0.77 KDM4C (0.41) HPGDSALDH1A1LMNAKMT2ACYP11B2
SCHEMBL30714688 0.76 TP53 (0.40) HPGDSLMNACYP11B2KDM4ETHRB
SCHEMBL30714642 0.76 HPGDS (0.36) SCN9AHPGDSKMT2ACYP11B2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250376461-A1 INDAZOLE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS UNIV LEUVEN KATH (BE) 2025-12-11 US disclosed
CN-119968362-A Indazole derivatives for the treatment of TRPM3 mediated disorders 勒芬天主教大学 2025-05-09 CN disclosed
EP-4499624-A2 INDAZOLE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS Katholieke Universiteit Leuven KU Leuven Research & Development (BE) 2025-02-05 EP disclosed
WO-2023230540-A2 INDAZOLE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2023-11-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250376461-A1 INDAZOLE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS TRPV3, TRPM2, TRPV1 SCN9A 518/4885HPGDS 671/4885PLAT 4674/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.